Biohaven Pharmaceutical
Founded Year
2013Stage
Acq - P2P | AcquiredTotal Raised
$80MValuation
$0000About Biohaven Pharmaceutical
Biohaven Pharmaceutical (NYSE: BHVN) is a clinical-stage biopharmaceutical company with a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company's product candidates are small molecules based on two distinct mechanistic platforms such as calcitonin gene-related peptide, or CGRP, receptor antagonists and glutamate modulators. It was founded in 2013 and is based in New Haven, Connecticut. In October 2022, Biohaven Pharmaceutical was acquired by Pfizern.6B.
Missing: Biohaven Pharmaceutical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Biohaven Pharmaceutical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Biohaven Pharmaceutical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Biohaven Pharmaceutical is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Biohaven Pharmaceutical Patents
Biohaven Pharmaceutical has filed 41 patents.
The 3 most popular patent topics include:
- Amines
- Calcium channel blockers
- Neurological disorders
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/8/2019 | 2/7/2023 | Monoclonal antibodies, Clusters of differentiation, Immune system, Immunology, Olfactory receptors | Grant |
Application Date | 1/8/2019 |
|---|---|
Grant Date | 2/7/2023 |
Title | |
Related Topics | Monoclonal antibodies, Clusters of differentiation, Immune system, Immunology, Olfactory receptors |
Status | Grant |
Latest Biohaven Pharmaceutical News
Nov 10, 2022
(marketscreener.com) William Blair & Co. erhöht sein Rating von Neutral auf Kaufen.https://de.marketscreener.com/kurs/aktie/BIOHAVEN-PHARMACEUTICAL-H-34757109/news/Biohaven-Pharmaceutical-Holding-Company-Ltd-William-Blair-Co-erhoht-seine-Kaufempfehlung-42274341/?utm_medium=RSS&utm_content=20221110
Biohaven Pharmaceutical Frequently Asked Questions (FAQ)
When was Biohaven Pharmaceutical founded?
Biohaven Pharmaceutical was founded in 2013.
Where is Biohaven Pharmaceutical's headquarters?
Biohaven Pharmaceutical's headquarters is located at 234 Church Street, New Haven.
What is Biohaven Pharmaceutical's latest funding round?
Biohaven Pharmaceutical's latest funding round is Acq - P2P.
How much did Biohaven Pharmaceutical raise?
Biohaven Pharmaceutical raised a total of $80M.
Who are the investors of Biohaven Pharmaceutical?
Investors of Biohaven Pharmaceutical include Pfizer, Connecticut Innovations, John Childs, Aperture Venture Partners, Venrock and 12 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.